StockData
Immix Biopharma, Inc. logo

Immix Biopharma, Inc. (IMMX) stock

IMMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$7.20−0.28 (-3.74%)

Close on Nov 17, 2026Market cap $515.08MP/E –Yield –

Earnings

Immix Biopharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Immix Biopharma's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 12, 2026after the close–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Immix Biopharma has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Immix Biopharma puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Immix Biopharma filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. News
  3. Update
  4. News
  5. Update
  6. Update
  7. Update
  8. News
  9. News
  10. News
  11. Update
  12. News
  13. News
  14. News
  15. News

See a number that looks wrong?